Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2026
Event: Results of the 2026 Annual Meeting of Stockholders held via live webcast.
Participation: 1,079,494 shares (approximately 40.74% of outstanding shares) were represented, establishing a quorum.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding corporate governance and voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Voting Results
The stockholders voted on five proposals. All proposals were approved by the requisite majority of votes cast.
- Proposal 1 (Election of Directors): Elected two Class III directors (Dr. Emer Leahy and Lewis H. Bender) to serve until the 2029 annual meeting.
- Proposal 2 (Auditor Ratification): Ratified the selection of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Stock Incentive Plan Amendment): Approved an amendment to the 2021 Stock Incentive Plan to increase the number of shares available for issuance by 150,000.
- Proposal 4 (ESPP Amendment): Approved an amendment to the 2024 Employee Stock Purchase Plan to increase the number of shares available for issuance by 25,000.
- Proposal 5 (Adjournment): Approved the authority to adjourn the meeting if necessary to solicit additional proxies.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It strictly reports the outcomes of the shareholder vote.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 30, 2026, for detailed descriptions of the proposals and director biographies.
- Confirm the impact of the 175,000 total new shares authorized (150,000 for the Incentive Plan and 25,000 for the ESPP) on potential future dilution.
- Review the upcoming 10-K or 10-Q filings for the fiscal year ending December 31, 2026, to obtain financial performance data not included in this 8-K.